Journals / The Journal of Pediatric Research / 2019 / Cilt: 6 - Sayı: 1

Evaluation of Anticoagulant Proteins and Fibrinolytic System Markers in Children with Pneumonia

Pages
24–28
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Evaluation of the coagulation system may help determine the severity of pneumonia in children and be used to monitor its clinical progress.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: Coagulation and fibrinolytic systems play an important role in the pathogenesis of complicated pneumonia.
📊
Key Findings & Data:This study aims to evaluate and compare coagulation and fibrinolytic system markers and natural anticoagulant proteins with acute phase reactants, such as C-reactive protein or procalcitonin in children with pneumonia.Materials and Methods: One hundred and fifteen patients and 87 healthy children were included in the study.
💡
Conclusion & Impact:Evaluation of the coagulation system may help determine the severity of pneumonia in children and be used to monitor its clinical progress.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Özet

Aim: Coagulation and fibrinolytic systems play an important role in the pathogenesis of complicated pneumonia. This study aims to evaluate and compare coagulation and fibrinolytic system markers and natural anticoagulant proteins with acute phase reactants, such as C-reactive protein or procalcitonin in children with pneumonia.Materials and Methods: One hundred and fifteen patients and 87 healthy children were included in the study. Patients were separated into two groups based on viral and bacterial pneumonia diagnosis. Coagulation and anticoagulation system markers were compared with acute phase reactants in children with pneumonia.Results: White blood cell numbers and D-dimer (DD) levels were higher in the pneumonia patients compared to the control group (p=0.001 and 0.001 respectively). Protein C activity and antithrombin activity in the patient group were significantly lower compared to the control group (p=0.001 and p=0.011 respectively). Acute phase reactants and DD levels in the bacterial pneumonia patients were higher compared to the viral pneumonia patients (p<0.05). Protein S activity, fibrin monomers and fibrin degradation products were not significantly different between the bacterial and viral pneumonia patients. Protein S activity in the bacterial pneumonia patients was lower compared to the viral pneumonia patients (p=0.040). There was no difference in terms of antithrombin activity and protein C activity.Conclusion: As a result, the relationships among acute phase proteins, anticoagulation proteins, and fibrinolytic system markers show that the coagulation and fibrinolytic system has an important role in pneumonia pathogenesis and associated inflammation. Evaluation of the coagulation system may help determine the severity of pneumonia in children and be used to monitor its clinical progress.

🔖

Cite This Article

YALAKI, Z., ALİOĞLU, B., ÇİFTÇİ, N., ARIKAN, F. İ. (2019). Evaluation of Anticoagulant Proteins and Fibrinolytic System Markers in Children with Pneumonia. The Journal of Pediatric Research, Cilt: 6 - Sayı: 1, 24–28. https://ajindex.com/articles/363004

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (16)

  1. Kocabas E, Ersoz D, Karakoc F, et al. The diagnosis and treatment in children with pneumonia in the community reconciliation report. Turkish Thoracic J 2009;10:1-26
  2. Henrickson KJ. Viral pneumonia in children. Sem Pediatr Infect Dis J 1998;9:217-33
  3. Ruuskanen O, Lahti E, Jennings LC, Murdoch DR. Viral pneumonia. Lancet 2011;377:1264-75
  4. De Wals P, Robin E, Fortin E, Thibeault R, Ouakki M, Douville-Fradet M. Pneumonia after implementation of the pneumococcal conjugate vaccine program in the province of Quebec, Canada. Pediatr Infect Dis J 2008;27:963-8
  5. Nieuwenhuizen L, de Groot PG, Grutters JC, Biesma DH. A review of pulmonary coagulopathy in acute lung injury, acute respiratory distress syndrome, and pneumonia. Eur J Haematol 2009;82:413-25
  6. Petäjä J. Inflammation and coagulation. An overview. Thromb Res 2011;127:34-7
  7. Quick G, Eisenberg P. Bedside measurement of D-dimer in the identification of bacteremia in the emergency department. J Emerg Med 2000;19:217-23
  8. Agapakis DI, Tsantilas D, Psarris P, et al. Coagulation and inflammation biomarkers may help predict the severity of community-acquired pneumonia. Respirology 2010;15:796-803
  9. Abraham E. Coagulation abnormalities in acute lung injury and sepsis Am J Respir Cell Mol Biol 2000;22:401-4
  10. Günther A, Mosavi P, Heinemann S, et al. Alveolar fibrin formation caused by enhanced procoagulant and depressed fibrinolytic capacities in severe pneumonia. Comparison with the acute respiratory distress syndrome. Am J Respir Crit Care Med 2000;161:454-62
  11. Arslan S, Ugurlu S, Bulut G, Akkurt I. The association between plasma D-dimer levels and community-acquired pneumonia. Clinics 2010;65:593-7
  12. Bartlett JG, Dowell SF, Mandell LA, File TM Jr, Musher DM, Fine MJ. Practice guidelines for the management of communityacquired pneumonia in adults. Infectious Diseases Society of America. Clin Infect Dis 2000;31:347-82
  13. Levi M, Schultz MJ, Rijneveld AW, van der Poll T. Bronchoalveolar coagulation and fibrinolysis in endotoxemia and pneumonia. Crit Care Med 2003;31:238-42
  14. Långström S, Peltola V, Petäjä J, Ruuskanen O, Heikinheimo M. Enhanced thrombin generation and depressed anticoagulant function in children with pneumonia. Acta Paediatr 2012;101:919-23
  15. Guo SC, Xu CW, Liu YQ, Wang JF, Zheng ZW. Changes in plasma levels of thrombomodulin and D-dimer in children with different types of Mycoplasma pneumoniae pneumonia. Zhongguo Dang Dai Er Ke Za Zhi 2013;15:619-22
  16. Proie